Zucara Therapeutics is a CDRD and MaRS Innovation portfolio company that is developing the first drug therapy to prevent hypoglycemia in people with diabetes.
Zucara Therapeutics' first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes.
Zucara was created in 2015 as a spin-out company by adMare BioInnovations (formerly known as CDRD, Canada’s national Centre for Drug Research and Development), and TIAP (formerly known as MaRS Innovation). The company is headquartered in Vancouver, British Columbia, with an office in Toronto, Ontario.
Zucara is developing ZT-01, a first-in-class, once-daily therapeutic to prevent insulin-induced hypoglycemia in patients using insulin therapy. ZT-01 is designed to inhibit somatostatin, a pancreatic hormone that impairs the glucagon response to hypoglycemia in people with insulin dependent diabetes.
Zucara is backed by Perceptive Xontogeny Venture Fund, The Leona M., Harry B. Helmsley Charitable Trust, JDRF International and others. This compan closed a $21M Series A financing on Mar 31, 2020. This brings Zucara's total funding to $28M to date.